""If a patient develops emergent depression or suicidal ideation during treatment, clinicians should discontinue the weight-loss medication and connect the patient with psychiatric support."
Eli Lilly, manufacturer of the tirzepatide weight-loss medication Zepbound, explicitly mentions "depression or thoughts of suicide" in its safety information."
Framing: assertive ·
First seen: 2026-09-09 ·
Last seen: 2026-09-09 ·
Spread: 1 articles